Bank of America’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,479
| Closed | -$543 | – | 8402 |
|
|
2025
Q2 | $543 | Sell |
1,479
-36,461
| -96% | -$12.2K | ﹤0.01% | 7655 |
|
|
2025
Q1 | $9.83K | Sell |
37,940
-18,899
| -33% | -$10.8K | ﹤0.01% | 7118 |
|
|
2024
Q4 | $31.9K | Buy |
56,839
+16,962
| +43% | +$10K | ﹤0.01% | 6737 |
|
|
2024
Q3 | $23.9K | Sell |
39,877
-143,851
| -78% | -$213K | ﹤0.01% | 6712 |
|
|
2024
Q2 | $496K | Sell |
183,728
-61,604
| -25% | -$232K | ﹤0.01% | 5346 |
|
|
2024
Q1 | $1.26M | Buy |
245,332
+90,863
| +59% | +$294K | ﹤0.01% | 4784 |
|
|
2023
Q4 | $83K | Buy |
154,469
+21
| +0% | +$11 | ﹤0.01% | 6451 |
|
|
2023
Q3 | $102K | Buy |
154,448
+154,447
| +15,444,700% | +$156K | ﹤0.01% | 6245 |
|
|
2023
Q2 | $2 | Buy |
+1
| New | +$3 | ﹤0.01% | 7639 |
|
|
2023
Q1 | – | Sell |
-17
| Closed | -$16 | – | 7918 |
|
|
2022
Q4 | $16 | Buy |
+17
| New | +$17 | ﹤0.01% | 8014 |
|
|
2022
Q2 | – | Sell |
-1
| Closed | – | – | 8111 |
|
|
2022
Q1 | $0 | Sell |
1
-6,987
| -100% | -$28K | ﹤0.01% | 8378 |
|
|
2021
Q4 | $42K | Buy |
+6,988
| New | +$48.2K | ﹤0.01% | 7281 |
|
Other funds holding ELEV
Bank of America's ELEV Position: Q3 2025 in Review
Bank of America sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 1,479 shares — an estimated $543 sold.
Bank of America first reported a position in ELEV in Q4 2021 and held it in 12 quarters. The position peaked at $1.26M in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.
- Bank of America reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
- Bank of America sold 1,479 Elevation Oncology shares in Q3 2025, an estimated $543.
- Bank of America first reported a position in Elevation Oncology in Q4 2021 and held it in 12 quarters.
- Bank of America's Elevation Oncology position peaked at $1.26M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.
Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.